This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1
by Zacks Equity Research
Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.
Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up
by Zacks Equity Research
Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.
3 GARP Stocks to Scoop up for Maximum Returns
by Zacks Equity Research
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. RMD, BAH and KTB are some stocks that hold promise.
Penumbra (PEN) Q1 Earnings Lag Estimates, Margins Expand
by Zacks Equity Research
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
by Zacks Equity Research
Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.
Globus Medical (GMED) Q1 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the first quarter of 2024.
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
by Zacks Equity Research
Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.
Henry Schein (HSIC) Tops Q1 Earnings, Lowers '24 Sales View
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter performance reflects a strong recovery from last year's cyber incident.
Here's How Much You'd Have If You Invested $1000 in ResMed a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Top Research Reports for Apple, Linde & Comcast
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Linde plc (LIN) and Comcast Corporation (CMCSA).
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.
Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.
DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its first-quarter performance.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline
by Zacks Equity Research
Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.
Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise
by Zacks Equity Research
Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.
4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts
by Ritujay Ghosh
Investing in defensive stocks like ResMed Inc. (RMD), Encompass Health Corporation (EHC), New Jersey Resources Corporation (NJR) and Global Water Resources, Inc. (GWRS) would be a wise idea during these times of uncertainty.
Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.
Envista (NVST) Q1 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.
BD (BDX) Q2 Earnings Surpass Estimates, FY24 View Revised
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.
Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts
by Zacks Equity Research
Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.
Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics
by Zacks Equity Research
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
Merit Medical (MMSI) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Merit Medical (MMSI) benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter.
CVS Health's (CVS) Q1 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
CVS Health's (CVS) Q1 performance is impacted by a decline in the Health Services segment due to continued pharmacy client price improvements.